Compare AL & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AL | NUVL |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | 160 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.1B |
| IPO Year | N/A | 2021 |
| Metric | AL | NUVL |
|---|---|---|
| Price | $64.71 | $102.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $62.50 | ★ $135.33 |
| AVG Volume (30 Days) | ★ 1.7M | 444.0K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $5.58 | $1,064.25 |
| P/E Ratio | $6.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.25 | $55.54 |
| 52 Week High | $64.97 | $113.02 |
| Indicator | AL | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 50.12 |
| Support Level | $63.44 | $98.65 |
| Resistance Level | $64.97 | $107.13 |
| Average True Range (ATR) | 0.11 | 4.31 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 19.70 | 55.75 |
Air Lease Corp is an aircraft leasing company based in the United States. It is engaged in the modern, fuel-efficient new technology commercial jet aircraft directly from aircraft manufacturers and leasing those aircraft to airlines throughout the world to generate attractive returns on equity. The company also sells aircraft from its fleet to third parties, including other leasing companies, financial services companies, airlines, and other investors, and offers fleet management services to investors and owners of aircraft portfolios for a management fee. Geographically, it derives a maximum of its revenue from the Europe and the rest from Asia Pacific, Middle East and Africa, Central America, South America, Mexico, the United States, and Canada.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.